With a market capitalization (market cap) of $1.09B — a measure of how much the company is worth — SI-BONE, Inc. ranks #2,392 among the 2,445 companies tracked, and 345th in Healthcare as of November 6, 2026. Shares trade at $24.24, down 0.12% on the day.
of 2,445 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 4, 2026. Ranking headline cap is the snapshot figure as of November 6, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Nov 4, 2026 | $1.12B | +29.23% | $24.95 |
| 2025 | Dec 31, 2025 | $866.89M | +46.05% | $19.72 |
| 2024 | Dec 31, 2024 | $593.57M | -30.31% | $14.02 |
| 2023 | Dec 29, 2023 | $851.76M | +81.04% | $20.99 |
| 2022 |
Ranking figure $1.09B as of November 6, 2026.
SI-BONE, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $24.24 as of November 6, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.12B on November 4, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 43,507,786 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.27T | -0.79% |
| #20 | Johnson & Johnson JNJ | $664.95B | +1.43% |
| #23 |
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 6, 2026, SI-BONE, Inc. (SIBN) is worth $1.09B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, SI-BONE, Inc.’s book equity is about $177.53M. Market cap is the market value of the outstanding shares. As of November 6, 2026, its market cap is $1.09B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
SI-BONE, Inc. ranks #2,392 among the 2,445 companies tracked on MarketCapLens. In Healthcare it ranks #345 of 351.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| Dec 30, 2022 |
| $470.49M |
| -37.31% |
| $13.60 |
| 2021 | Dec 31, 2021 | $750.53M | — | $22.21 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2025
| $514.78B |
| +1.07% |
| #30 | Merck & Co., Inc. MRK | $361.96B | -0.16% |
| #31 | UnitedHealth Group Incorporated UNH | $353.79B | -0.40% |
| #37 | Novartis AG NVS | $307B | +0.38% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2389 | Londian Wason New Energy Tech, Inc. Unsponsored ADR FOIL | $1.09B | +11.83% |
| #2390 | USA Rare Earth Inc USAR | $1.09B | +10.85% |
| #2391 | Cementos Pacasmayo S.A.A. CPAC | $1.09B | 0.00% |
| #2393 | Five Star Bancorp FSBC | $1.08B | +0.82% |
| #2394 | Napco Security Technologies, Inc. NSSC | $1.08B | +0.83% |
| #2395 | Lindsay Corporation LNN | $1.08B | -0.51% |
SI-BONE, Inc.’s ranking market cap of $1.09B comes from the same snapshot as the rest of this site, as of November 6, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 43,507,786. The historical market-cap series last observed $1.12B on November 4, 2026.
Over the past year, SI-BONE, Inc.’s market cap is up 67.74%, using historical market-cap records rather than today’s share count applied to past prices.
SI-BONE, Inc. (SIBN) shares trade at $24.24, down 0.12% on the day, as of November 6, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.